Evidence map›Paper›PMID 28538394›Full record

Observational studyMedicine2017

123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders.

Susanna Nuvoli, Angela Spanu, Maria Rita Piras, Antonio Nieddu, Aldo Mulas, Gaia Rocchitta, Grazia Galleri, Pier Andrea Serra, Giuseppe Madeddu

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. [Molecular imaging and biology · 2020
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Roles of cardiac sympathetic neuroimaging in autonomic medicine.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2018
    Review
  12. The Utility of the Combined Use ofYonago acta medica · 2018
    Article
  13. Clinical imaging in dementia with Lewy bodies.Evidence-based mental health · 2018
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Susanna NuvoliNuclear Medicine Unit Neurology Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Geriatric Unit, Policlinico Sassarese Pharmacology Unit Internal Medicine Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.
Angela Spanu
Maria Rita Piras
Antonio Nieddu
Aldo Mulas
Gaia Rocchitta
Grazia Galleri
Pier Andrea Serra
Giuseppe Madeddu
Brain Physiology Lab · FRPoliclinico di Modena · ITUniversity of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the clinical usefulness of the combined use of I-ioflupane brain single photon emission computed tomography (SPECT) and I-metaiodobenzylguanidine (MIBG) cardiac scintigraphy in discriminating uncertain parkinsonism with vascular lesions in striatal nuclei at magnetic resonance imaging (MRI). Forty-three consecutive patients with uncertain parkinsonism and vascular lesions at MRI in striatal nuclei were retrospectively evaluated; the uncertain differential diagnosis was between Parkinson's disease and vascular parkinsonism (PD/VP) in 22 patients, between PD and other neurodegenerative parkinsonism (PD/PS) in 11 patients and between Lewy body dementia and Alzheimer disease (LBD/AD) in the remaining 10 cases. All patients underwent I-ioflupane SPECT with striatal dopaminergic activity determination as binding potentials (BP; cut-off: 3.3). I-MIBG cardiac planar scintigraphy was performed 2 weeks later, in early (15 minutes) and delayed (240 minutes) phases also calculating heart to mediastinum (H/M) ratio (cut-off: 1.56). I-Ioflupane uptake was normal in 9 patients with BP values >3.3, while it was reduced in 34/43 cases with BP values <3.3 at least in one of the striatal nuclei. I-MIBG uptake was normal in 21/43 patients (5 of whom with normal and 16 with I-ioflupane striatal defects) showing the H/M ratio >1.56 in all cases; the uptake was reduced in 22/43 cases, (4 of whom were normal and 18 were with I-ioflupane striatal defects) with the H/M ratio <1.56 in all cases. No statistical differences were found when early and delayed H/M ratios were mutually compared. Combining the 2 radioisotopic procedures, a more reliable diagnosis was achieved in 39/43 cases properly classifying 13 PD, 10 VP, 7 PS, 5 LBD, and 4 AD. However, the diagnosis remained uncertain in four patients with normal I-ioflupane and reduced I-MIBG uptake. The results of the present study confirmed that in uncertain parkinsonian syndromes associated with vascular lesions in striatal nuclei, brain I-ioflupane SPECT alone did not prove able to discriminate between the different forms of disease. Only the association with I-MIBG cardiac scintigraphy, also with the early acquisition alone, allowed the most appropriate diagnosis in 90.7% of our cases. However, patients with normal I-ioflupane and reduced I-I-MIBG uptakes need a close clinical and instrumental follow-up as sympathetic damage could precede striatal disorders in the early stage of PD and LBD.

Indexed as

Multimodal ImagingTomography, Emission-Computed, Single-Photon3-IodobenzylguanidineAgedAged, 80 and overBrainDiagnosis, DifferentialFemaleHeartHumansMagnetic Resonance ImagingMaleMiddle AgedNortropanesParkinsonian DisordersRadiopharmaceuticals3-IodobenzylguanidineioflupaneNortropanesRadiopharmaceuticals

Identifiers

PMID28538394
PMCPMC5457874
OpenAlexW2617661550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.